Copyright
©2013 Baishideng Publishing Group Co.
World J Cardiol. Jul 26, 2013; 5(7): 247-253
Published online Jul 26, 2013. doi: 10.4330/wjc.v5.i7.247
Published online Jul 26, 2013. doi: 10.4330/wjc.v5.i7.247
Table 1 Baseline characteristics of study population: Clinical, laboratory and imaging data n (%)
Variables | n = 86 |
Male gender | 67 (77.9) |
Age (yr) | 55.87 ± 11.85 |
Background diseases | |
Stage-1 (malignant) hypertension | 14 (16.3) |
Stage-2 hypertension | 65 (75.6) |
Diabetes mellitus | 34 (39.5) |
Smoking | 61 (70.9) |
Clinical features of left ventricular dysfunction | 23 (26.7) |
Left ventricular hypertrophy | 29 (33.7) |
Coronary artery disease | 72 (83.7) |
Blood pressure | |
Systolic (mmHg) | 170.15 ± 20.10 |
Diastolic (mmHg) | 98.38 ± 10.55 |
Antihypertensive drugs (n) | 3.07 ± 0.69 |
Indication criteria | |
Hypertension resistant to standard medication | 71 (82.6) |
Renal bruit | 53 (61.6) |
Serum creatinine (mg/dL) | 20 (23.3) |
Stenosis | |
Bilateral | 23 (26.7) |
Coronary angiography | |
Single vessel disease | 25 (29.1) |
Double vessel disease | 14 (16.3) |
Triple vessel disease | 28 (32.6) |
Normal vessel | 19 (22.1) |
Table 2 Blood pressure, antihypertensive medication, serum creatinine and glomerular filtration rate initial vs follow-up measurements
Time of follow-up | mean ± SD | P value |
Systolic blood pressure (mmHg) | 170.15 ± 20.10 | < 0.0001 |
Baseline | ||
1 mo | 146.60 ± 17.32 | |
6 mo | 144.23 ± 18.19 | |
Diastolic blood pressure (mmHg) | 98.38 ± 10.55 | < 0.0001 |
Baseline | ||
1 mo | 89.88 ± 9.22 | |
6 mo | 88.26 ± 9.79 | |
Antihypertensive drugs (n) | 3.07 ± 0.69 | < 0.0001 |
Baseline | ||
1 mo | 2.37 ± 0.84 | |
6 mo | 2.25 ± 0.94 | |
Serum creatinine (mg/dL) | 1.21 ± 0.66 | 0.964 |
Baseline | ||
48 h | 1.29 ± 0.88 | |
1 mo | 1.33 ± 1.27 | |
6 mo | 1.21 ± 0.79 | |
GFR estimation (mL/min) | 65.71 ± 25.20 | 0.546 |
Baseline | ||
6 mo | 66.68 ± 25.03 |
Table 3 Levels of sIL-2R, alanine aminotransferase, and hepatitis B virus DNA in the sera of patients with chronic HBV infection (mean ± SD)
Group1 | n | mean ± SD | P value |
Age (yr) | 0.51 | ||
A | 26 | 56.81 ± 13.87 | |
B | 49 | 54.80 ± 11.55 | |
Initial systolic BP (mmHg) | 0.01 | ||
A | 26 | 179.31 ± 20.32 | |
B | 49 | 166.00 ± 18.76 | |
Initial diastolic BP (mmHg) | 0.04 | ||
A | 26 | 101.92 ± 10.90 | |
B | 49 | 96.79 ± 10.14 | |
Initial mean BP (mmHg) | 0.01 | ||
A | 26 | 141.00 ± 17.73 | |
B | 49 | 129.00 ± 16.76 | |
No. of medications | 0.01 | ||
A | 26 | 3.26 ± 0.77 | |
B | 49 | 2.87 ± 0.57 | |
Creatinine (mg/dL) | 0.07 | ||
A | 26 | 1.38 ± 0.48 | |
B | 49 | 1.11 ± 0.66 | |
Diameter of stent | 0.23 | ||
A | 26 | 5.76 ± 0.94 | |
B | 49 | 6.05 ± 0.98 | |
Percent of renal artery stenosis (RAS) | 0.05 | ||
A | 26 | 87.65 ± 7.71 | |
B | 49 | 83.79 ± 8.40 | |
GFR (mL/min) | 0.01 | ||
A | 26 | 54.03 ± 24.22 | |
B | 49 | 72.97 ± 25.43 | |
Duration of HT (yr) | 0.55 | ||
A | 26 | 4.00 ± 3.96 | |
B | 49 | 3.40 ± 3.32 |
Table 4 Clinical features of resistant hypertensive group: Responsive vs unresponsive to percutaneous transluminal renal artery n (%)
Group A | Group B | P value | ||
n = 26 | n = 49 | |||
Male gender | 24 (92.3) | 33 (67.3) | 0.016 | |
Smoker | 22 (84.6) | 33 (67.4) | 0.1 | |
Ischemic heart disease | 21 (80.8) | 35 (71.4) | 0.376 | |
Diabetes mellitus | 8 (30.8) | 19 (38.8) | 0.49 | |
C/f of LVF | 5 (19.2) | 11 (22.4) | 0.746 | |
Smoking | 22 (84.6) | 33 (67.4) | 0.1 | |
Renal bruit | 20 (76.9) | 29 (59.2) | 0.124 | |
Refractory HT | 23 (88.5) | 37 (75.5) | 0.182 | |
LVH | 14 (53.9) | 14 (28.6) | 0.031 | |
LAD | 19 (73.1) | 34 (69.4) | 0.733 | |
TVD | 12 (46.2) | 13 (26.5) | 0.08 | |
Renal artery stenosis | Unilateral RAS | 15 (57.7) | 40 (81.6) | 0.026 |
(unilat vs bilat) | Bilateral RAS | 11 (42.3) | 9 (18.4) | |
LMCA disease | Absent | 23 (88.5) | 47 (95.9) | 0.218 |
Present | 3 (11.5) | 2 (4.1) |
Table 5 Multivariate analysis: The independent predictors for poor blood pressure response after percutaneous transluminal renal artery
Variables | UnivariateP value | Multivariate analysis | 95%CI | ||
P value | β | Expβ | |||
Male sex | 0.02 | 0.046 | 1.797 | 6.032 | 1.028–35.380 |
High mean SBP | 0.01 | NS | |||
High mean DBP | 0.05 | NS | |||
High mean BP | 0.09 | 0.013 | -0.044 | 0.957 | 0.925–0.991 |
Low GFR (< 60 mL/min) | 0.01 | 0.015 | 1.377 | 3.965 | 1.308–12.020 |
LVH | 0.03 | NS | |||
Drugs (n) | 0.01 | NS | |||
Bilateral vs unilateral RAS | 0.02 | NS | |||
Percent of stenosis | 0.06 | NS | |||
Presence of TVD | 0.09 | NS | |||
Constant | 2.365 | 10.65 |
- Citation: Prajapati JS, Jain SR, Joshi H, Shah S, Sharma K, Sahoo S, Virparia K, Thakkar A. Response of blood pressure after percutaneous transluminal renal artery angioplasty and stenting. World J Cardiol 2013; 5(7): 247-253
- URL: https://www.wjgnet.com/1949-8462/full/v5/i7/247.htm
- DOI: https://dx.doi.org/10.4330/wjc.v5.i7.247